Press Releases

Oct 13, 2016 • 7:05 AM EDT Matinas BioPharma to Present at the 2nd Annual Dawson James Securities Growth Stock Conference

Sep 28, 2016 • 7:00 AM EDT Matinas BioPharma Commences Patient Dosing in NIH-Sponsored Phase 2a Study with Lead Anti-Infective Candidate MAT2203

Sep 13, 2016 • 7:05 AM EDT Matinas BioPharma Completes Private Placement of $8.0 Million

Sep 7, 2016 • 7:05 AM EDT Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Prophylaxis of Invasive Fungal Infections by U.S. FDA

Sep 6, 2016 • 7:05 AM EDT Matinas BioPharma to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13, 2016

Jul 13, 2016 • 7:00 AM EDT Matinas BioPharma Announces Presentation of Cryptococcal Meningitis Preclinical Data of MAT2203 at AIDS-Associated Mycosis Meeting 2016

Jun 22, 2016 • 7:05 AM EDT Matinas BioPharma Receives Issuance of Key U.S. Patent for Novel Lipid-Crystal Nano-Particle Cochleate Formulation Technology

Jun 20, 2016 • 7:35 AM EDT Matinas BioPharma Presents Preclinical Data of MAT2501 at ASM Microbe/ICAAC 2016

Jun 8, 2016 • 7:00 AM EDT Matinas BioPharma Announces Acceptance of Abstract on Efficacy and Tolerability of Encochleated Ibuprofen in Rat Carrageenan-Induced Paw Inflammation Model for EULAR 2016

Mar 31, 2016 • 7:05 AM EDT Matinas BioPharma Reports 2015 Financial Results and Provides Business Update